Clenbuterol has a reputation as a "fat burner" that supposedly preserves muscle while dieting. This reputation has made it one of the most famous drugs in bodybuilding and fitness, and at the same time - the hero of numerous doping scandals. The editorial compares what is expected of clenbuterol in the sports environment and what is actually known from human studies.
How Clenbuterol got into sports
Clenbuterol's path to sports began not with human medicine, but with animal husbandry. In the 1980s, it became known that beta-2 agonists change the composition of cattle carcasses: less fat, more muscle. These data quickly spread among bodybuilders who were looking for means for pre-competition weight cutting.
In the early 1990s, clenbuterol came into the spotlight in athletics: in 1992, German sprinters Katrin Krabbe and Grit Breuer were disqualified after testing positive for clenbuterol. Since then, the drug has constantly appeared in anti-doping reports.
The most famous episode was the case of the cyclist Alberto Contador, in whose sample during the Tour de France in 2010 a very small amount of clenbuterol was found. The athlete explained it as contaminated meat, but the Court of Arbitration for Sport in 2012 did not accept this version, and Contador lost the title.
Other well-known cases, including five soccer players of the Mexican national team in 2011, ended with a different conclusion: their positive tests were linked to the consumption of contaminated meat. This shows how complicated the situation is with this substance.
Expectations: what "sports folklore" promises
In unofficial sources, clenbuterol is endowed with a whole set of properties. Here are the most common of them:
- quick "burning" of subcutaneous fat;
- preservation or even muscle growth during a calorie deficit;
- increasing endurance and "aerobic power";
- suppression of appetite;
- “mild” compared to steroids because it is “not a hormone”.
Some of these ideas have a physiological basis: beta-2 stimulation does indeed enhance lipolysis and increase energy expenditure. The problem is the scale of the effect, its sustainability and the price that has to be paid for it.
Much of the historical reputation came from animal experiments, whose doses cannot be directly transferred to people. Controlled human studies published in 2025 and 2026 have since demonstrated anabolic effects, so the earlier claim that the evidence is almost entirely animal-based needs updating.
Claims about the "mildness" of the drug should be considered separately: the absence of a hormonal nature does not make the substance safe. In contrast, the cardiovascular risks of Clenbuterol are different from those of steroids, but no less serious.
Reality: what human studies show
There are few controlled studies of clenbuterol in healthy people. One of the most cited is the work of Jessen et al. (2020): in young men, the drug increased resting energy expenditure and fat oxidation, as well as mTOR phosphorylation in muscles. However, this is a short-term study that did not measure long-term effects on body composition.
Compared to the energy deficit created by diet and physical activity, the additional effect of beta-agonists in humans is modest. In addition, due to desensitization of beta-2 receptors, the metabolic response weakens over time.
Effects depend on the outcome. A 2025 trial in 11 healthy men found reduced maximal oxygen uptake and exercise capacity despite increased lean mass. A resistance-training trial published on 12 September 2026 found larger gains in lean mass and strength, but no greater reduction in fat mass than placebo.
These newer trials update the older evidence base; they do not establish safe use, lasting benefit or muscle preservation during every dieting scenario. In the 2026 study, much of the extra gain diminished after discontinuation and detraining.
Price: health risks
The most frequent unwanted effects of clenbuterol are tremors, palpitations, insomnia, headache, muscle cramps, sweating. They directly follow from the mechanism of action and develop already in small doses.
More serious risks involve the heart. Toxicology centers describe tachycardia, arrhythmias, myocardial ischemia in young people. An Australian analysis of calls to a poison control center (Brett et al., 2014) found that the majority of cases were related to the use of clenbuterol for weight loss or bodybuilding, and a proportion of patients required hospitalisation.
Hypokalemia, caused by the movement of potassium inside the cells, increases the risk of rhythm disturbances. Hyperglycemia and increased lactate are also often observed. Hoffman et al. (2001) described a case in which tachycardia and electrolyte disturbances following clenbuterol administration lasted significantly longer than is usually the case with beta-agonist poisoning, due to the long half-life.
A separate risk is products from unofficial sources, where the actual content of the drug may differ significantly from the declared one. For a substance that is dosed in micrograms, an error of even several times can lead to poisoning.
| Expectation | What is known |
|---|---|
| Fast fat burning | Increase in energy expenditure in humans is moderate, weakens over time |
| Preservation of muscles | Human trials now show lean-mass gains; lasting benefit remains uncertain |
| Endurance | Reduced cardiorespiratory fitness in a 2025 trial |
| “Mildness” and safety | Tachycardia, arrhythmias, hypokalemia, described cases of myocardial ischemia |
| Anti-doping risks | Prohibited at all times; substantial sporting sanctions are possible |
Anti-doping status and the problem of contaminated meat
On the WADA Prohibited List, clenbuterol belongs to category S1.2 "Other Anabolic Agents" and is prohibited at all times - both during and outside of competition. Unlike some inhaled beta-2 agonists, there is no approved therapeutic threshold for clenbuterol.
Due to the risk of eating meat from animals illegally given clenbuterol, athletes in some countries may inadvertently test positive. Guddat et al (2012) described that samples from athletes returning from certain regions showed low concentrations of clenbuterol consistent with food contamination.
WADA recognized this problem and issued clarifications to laboratories and anti-doping organizations regarding the evaluation of low concentrations of clenbuterol in light of possible meat contamination. However, the responsibility of the athlete remains strict, and each case is considered individually.
Practical advice for athletes competing in regions with a known contamination problem is to be careful with meat of unknown origin and follow the recommendations of their national anti-doping organization.
Editorial conclusions
Animal data and acute metabolic findings explain the original popularity. More recent human trials add evidence of lean-mass and strength effects, while fat-loss claims, durability and safety require separate assessment.
Instead, the risks are well documented: tachycardia, arrhythmias, hypokalemia, cases of myocardial ischemia have been described. A long half-life makes poisoning prolonged.
For athletes, clenbuterol is also a serious anti-doping risk, including the possibility of accidental ingestion with contaminated meat.
We also advise you to read "Clenbuterol: mechanism of action and effect on the body", "Clenbuterol / Ephedrine" comparison and the article "Heart rhythm disorders".
References
- Jessen S, Solheim SA, Jacobson GA, et al. Beta2-adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. Drug Test Anal. 2020;12(5):610–618.
- Brett J, Dawson AH, Brown JA. Clenbuterol toxicity: a NSW poisons information centre experience. Med J Aust. 2014;200(4):219–221.
- Hoffman RJ, Hoffman RS, Freyberg CL, et al. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels. J Toxicol Clin Toxicol. 2001;39(4):339–344.
- Guddat S, Fußhöller G, Geyer H, et al. Clenbuterol – regional food contamination a possible source for inadvertent doping in sports. Drug Test Anal. 2012;4(6):534–538.
- Mersmann HJ. Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action. J Anim Sci. 1998;76(1):160–172.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; Ñинна ÑедакÑÑÑ.
